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Abstract 
Background: Vasomotor symptoms (VMS) are the hallmarks of menopause, occurring in 
approximately 75% of postmenopausal women in the UK and are severe in 25%. 
Objectives: To identify which treatments are most clinically effective for the relief of VMS for non-
hysterectomized women in natural menopause. 
Search Strategy: English publications in MEDLINE, Embase and The Cochrane Library up to 13th 
January 2015 were searched.  
Selection Criteria: Randomized trials (RCTs) of treatments for women with a uterus for the 
outcomes of frequency of VMS (up to 26 weeks), vaginal bleeding and discontinuation.  
Data Collection and Analysis: Bayesian network meta-analysis (NMA) using mean ratios (MRs) and 
odd ratios (ORs).  
Main Results: Across the three networks, 47 RCTs of 16 treatment classes (N=8326 women) were 
included. When compared to placebo, transdermal oestradiol and progestogen (O+P) had the 
highest probability of being the most effective treatment for VMS relief (69.8%) (MR: 0.23 [95%CrI 
(0.09, 0.57)] whereas oral O+P was ranked lower than transdermal O+P, although oral and 
transdermal O+P were no different for this outcome (MR: 2.23 [95%CrI (0.7, 7.1)]. Isoflavones and 
black cohosh were more effective than placebo, though not significantly better than O+P. Not only 
were SSRIs or SNRIs found ineffective in relieving VMS but they also had significantly higher odds of 
discontinuation than placebo. Limited data were available for bleeding therefore no conclusions 
could be made.  
Conclusions: For non-hysterectomized women, transdermal O+P was the most effective treatment 
for VMS relief. 
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Tweetable abstract: Which treatment best relieves menopause flushes? Results from the #NICE 
guideline network meta-analysis 
 
Introduction  
Menopausal symptoms are extremely common. Vasomotor symptoms (VMS) comprising hot flushes 
and night sweats are the most common menopausal symptoms occurring in approximately 75% of 
postmenopausal women, with 25% of these being severely affected in the UK1. The duration and 
severity of menopausal symptoms experienced are not uniform – symptoms may develop in the 
years before the final menstrual period and may persist for a few years or for many years in 
postmenopause.  
Hot flushes often begin as the sudden sensation of heat centred on the upper chest and face. In 
some instances, this will become generalised, lasting for several minutes, and can be associated with 
profuse perspiration, palpitations or anxiety which may be very distressing and limit activities of 
daily living, particularly when they occur repeatedly during the day and at night. At night, hot flushes 
and night sweats will often cause insomnia that leads to fatigue. The mechanism of VMS appears to 
involve the central nervous system, possibly due to narrowing of the thermoregulatory-neutral zone 
in women with hot flushes, associated with instability of the skin blood vessels2.  
Different treatment options, pharmacological and non-pharmacological, have been used by women 
to relieve the VMS during menopause. Some of these treatments, such as hormone replacement 
therapy (HRT) target a “replacement” of oestrogen levels HRT comprises synthetic hormones 
including oestradiol, conjugated equine oestrogens, oestradiol valerate and several synthetic 
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progestogens as well as tibolone which exhibits estrogenic, progestogenic and androgenic effects. 
Other treatments, such as herbal medicines and psychological therapies may work in different ways. 
As VMS may resolve naturally, some women simply do not wish to take hormones, while for others 
HRT is contraindicated, for example women who have (or are at high risk of) hormone-dependent 
cancer.  
We aim to present the evidence obtained via a systematic review (SR), using network meta-analysis 
(NMA), of pharmacological and non-pharmacological treatments for the relief of VMS, relief of 
adverse events (such as vaginal bleeding)and discontinuation. This NMA formed part of the evidence 
underpinned the development of National Institute of Health and Care Excellence (NICE) Menopause 
Guideline (NG23) (https://www.nice.org.uk/guidance/ng23 )3.  The use of NMA is recommended in 
healthcare decision making when multiple treatments are considered for one indication and these 
treatments have not been directly compared in the same trials.  
 
Methods 
Systematic Reviews 
The protocol of the SR was agreed by the Guideline Development Group (GDG) (Appendix S1), was 
conducted as part of the development of NICE guideline on menopause (NG23) 
https://www.nice.org.uk/guidance/ng23 and is reported according to the PRISMA extension 
statement for systematic reviews incorporating NMAs of health care interventions4.. A cost-
effectiveness model using results from this NMA, in addition to other evidence, were used by the 
GDG to make recommendations in the guideline. In summary, the SRs included only randomised 
controlled trials (RCTs) that assessed pharmacological and/or non-pharmacological treatments for 
reducing the frequency of VMS, treatment discontinuation and vaginal bleeding for women aged 45 
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years or older with a diagnosis of natural menopause (defined as amenorrhea for at least 12 
consecutive months).  
The population in the NMA protocol was stratified into three groups that formed three networks of 
connected treatments: women with a uterus, women without a uterus, women with a history or at 
risk of breast cancer. This paper presents the results of the first network (women with a uterus). For 
non-oestrogenic treatments we included studies of women without a uterus as their effect was 
found to be clinically similar. For studies investigating oestrogen plus progestogen we included 
mixed studies of women with a uterus and without a uterus as long as more than two thirds (66.6%) 
of the study sample were women with a uterus (Appendix S1). 
The efficacy endpoint was the frequency of VMS at the end of treatment, whereas vaginal bleeding 
and treatment discontinuation were considered measures of adverse events. Although distress 
caused by VMS may have been an equal relevant outcome for women in menopause, the frequency 
of VMS was the most commonly reported outcome in studies, and the Guideline Committee 
highlighted that VMS were highly prevalent among women seeking treatment for menopausal 
symptoms. Vaginal bleeding and treatment discontinuation were prioritised due to their importance 
on continuity of healthcare, costs of further treatment, and long-term impact. . 
The time points of outcomes recorded were guided by clinical decision on the minimum duration of 
a trial for the intervention to be effective.  Non-hormonal treatments were considered by the GDG 
to take a minimum of four weeks to be effective, whilst hormonal treatments were considered to 
take longer (12 weeks). As shorter-term outcomes were the focus of this review, 26 weeks was 
considered to be the maximum follow-up time we would include, to avoid long-term changes in 
treatment efficacy that might cause heterogeneity within the network. 
All searches were conducted in MEDLINE  Embase and The Cochrane Library up to 13th January 2015 
restricted to English written articles according to the parameters stipulated within the NICE 
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Guidelines Manual 2015 (https://www.nice.org.uk/article/PMG20/chapter/4-Developing-review-
questions-and-planning-the-evidence-review) (Appendix S2),.  Literature reviews, posters, letters, 
editorials, comment articles, unpublished studies and studies not in English were excluded. Full 
search strategies were published as part of the full NICE guideline 
(http://www.nice.org.uk/guidance/ng23/evidence/appendices-ag-559549262 ). 
Search strategies were quality assured by cross-checking reference lists of highly relevant papers and 
comparing with search strategies in other SRs. 
 
Data extraction 
Data were double extracted in a structured form using a guide developed by the authors for Data 
Extraction for Complex Meta-anALysis (DECiMAL) independently by two reviewers55.  Discrepancies 
in data extraction were addressed by a senior reviewer who resolved any conflicts.  
The quality of the studies was evaluated using two domains (risk of bias, indirectness) of the 
‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ 
developed by the international GRADE working group (http://www.gradeworkinggroup.org/)6. 
Detailed results for risk of bias domains are shown in Table S2. 
 
Statistical models 
NMA was formulated to synthesise direct and indirect evidence of treatments’ effects to reduce the 
frequency of VMS, treatment discontinuation and vaginal bleeding using the software WinBUGS 
version 1.4.3. We used statistical models for both fixed and random effects that allowed inclusion of 
multi-arm trials and accounted for the correlation between arms in the trials with any number of 
trial arms7. A class effect model was selected for the NMA with the underlying assumption that the 
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effectiveness of different treatments under the same class would be comparable. This decision was 
made to maximise the availability of data and borrow strength from different trials. Data were 
available on dosing for many treatments, but the sparseness of the networks meant that it was 
necessary to borrow strength on dosing within treatments by assuming different doses of the same 
treatment had the same class effects (fixed effects model (FE)). A model allowing for within-class 
variability was also assessed to check if it improved model fit and reduced heterogeneity (random 
effects model (RE)). Two RE models for this were explored: an exchangeable dose effects model, 
where the pooled relative effects of different treatment doses were assumed to be randomly 
distributed within each treatment with a common variance (requiring modelling using a second 
variance parameter); and a fixed dose effects model, where the pooled relative dose effects are 
assumed equal for all doses of a treatment. For treatments where dosing information was not 
available, the relative effect at the dose level was assumed to be equal to the treatment effect in 
both models. 
 
WinBUGS code was adapted from the Dias et al 2011 and is available from the NICE appendices 
(https://www.nice.org.uk/guidance/ng23/evidence/appendices-ik-559549264 ). The following prior 
distributions were used: 
• Log mean ratios (MRs)  in the comparator arms for each study were normally distributed 
with mean of zero and variance of 1000 
• Pooled log MRs at the treatment or class level (depending on model used) were normally 
distributed with mean of zero and variance of 1000 
• Between-study standard deviation followed a uniform distribution between zero and two 
• Within-class standard deviation followed a uniform distribution between zero and two 
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Placebo was selected as the baseline comparator for all networks as it was the treatment arm most 
commonly evaluated in RCTs.  As no dependency on time was identified in exploratory analyses, 
discontinuation of treatment and vaginal bleeding were treated as dichotomous outcomes and were 
modelled on the log-odds ratio scale (Figure S2). Exploratory analyses also showed that baseline 
frequency of VMS followed an overdispersed Poisson distribution thus it was not appropriate to use 
a standard Poisson distribution to model the frequency of VMS (Figure S3). The negative binomial 
distribution can be used to model an overdispersed Poisson distribution, by including a parameter 
that accounts for the overdispersion8,9,10. The mean of this negative binomial is interpreted as the 
rate of the over-dispersed Poisson and  can be approximated by a normal distribution. We therefore 
model the mean using a log link function and relative treatment effects are estimated as log-mean 
ratios. Our motivation was to model data as closely as possible to the mechanism by which they 
were generated (i.e. from an overdispersed Poisson distribution) and this approximation provided a 
simple computational solution whilst retaining the interpretation of the pooled effect as mean rates 
of VMS 
On the log mean ratio scale, final and change from baseline frequencies of VMS could not be pooled, 
so the latter was transformed so that all effects could be modelled as final frequencies. A correlation 
coefficient of 0.55 was used to estimate final frequencies from change from baseline This was 
calculated from two included studies which reported baseline, final and change from baseline results 
in full11,12. 
All three models (FE, RE with fixed dose effects, RE with exchangeable dose effects) were compared 
based on residual deviance and deviance information criteria (DIC)7,13. Between-studies 
heterogeneity estimates from random effects models are presented as median and 95% credible 
intervals (95%CrI). 
Inconsistency in the networks was tested in closed loops of treatment comparisons by node-
splitting14. This technique allows the splitting of direct and indirect information contributing to each 
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treatment effect. The difference between these contributions can be statistically tested, with a 
rejection of the null hypothesis indicating significant inconsistency in the network. 
The output of the NMA was expressed as the probability of each treatment being the best for an 
outcome (based on the proportion of Markov chain simulations in which a treatment ranked first) 
and the ranking of treatments (presented as median rank and its 95%CrI). The estimation of 
summary estimates (mean ratios [MRs] or odds ratios [ORs]) were also calculated for comparisons of 
the direct and indirect evidence using medians and 95%CrIs from the posterior distributions.   
Two types of sensitivity analyses were predefined in the NMA protocol. The first focused on 
changing the value of the correlation coefficient used to estimate final frequencies of VMS from 
change from baseline, from 0.55 in the original analysis to a typically assumed correlation between 
baseline and follow-up of 0.75. The second analysis tested if differences in treatment efficacy could 
be explained by differences in dosing. Studies investigating the treatment of low dose oral oestradiol 
plus progestogen were removed from the analysis to determine if this dose was reducing the overall 
efficacy of oral oestradiol plus progestogen in the model. The final results were not found to be 
sensitive to either of these changes. 
A further post-hoc sensitivity analysis was considered to investigate the effect of including mixed 
population studies (women with and without a uterus) of oestrogen plus progestogen. However, as 
there was only a single study32 that included mixed populations for this treatment comparison, 
exclusion of the study removed oestrogen plus progestogen oral from the network and prevented 
estimation of the efficacy of this treatment. No other results were affected by the exclusion of this 
study. 
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Results  
47 RCTs matched the protocol, presented information for at least one of the outcomes and were 
included in the NMA (Figure S1).  For the two first networks (frequency of VMS and discontinuation 
of treatment), DIC suggested that there was a small difference between any of the models 
(differences less than 5 points are not considered meaningful) (Tables S7). However, the residual 
deviance for the random effects model with fixed dose effects for both these networks was slightly 
closer to the number of unconstrained data points than either of the other models (for the fixed 
effects and random effects with exchangeable dose effects respectively). Therefore, the results of 
the random effects model with fixed dose effects are presented for these two networks. For the 
network of vaginal bleeding, the results of the fixed effects model are presented, as the estimate of 
heterogeneity for the random effects model was unstable, and strongly influenced by the prior 
distribution. 
 
a. Reducing the frequency of VMS 
A total of 32 RCTs of 12 treatment classes (placebo, sham acupuncture, oestrogen plus progestogen 
non-oral, oestrogen plus progestogen oral, tibolone, raloxifene, SSRIs/SNRIs, isoflavones, Chinese 
herbal medicine, black cohosh, multibotanicals, acupuncture) with a sample size of 4165 women 
were included for the NMA for VMS (Figure 1, Table S1). Two included RCTs was at very high risk of 
bias and 13 were high risk (Table S2). The other 21 RCTs were low or moderate risk. The combination 
of oestrogen plus progestogen via patches was found to be better than placebo (MR 0.23 95%CrI 
(0.09, 0.57)) at relieving VMS for women in menopause and had the highest probability of being the 
best treatment (68.9%) (Figure 2A, Table 1). Although, the 95%CrI for combination of oral oestrogen 
plus progesterone compared to placebo was wide (MR 0.52 (0.25, 1.06)), the point estimate 
suggested that it may have good efficacy, similar to that of transdermal oestrogen plus progestogen. 
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In addition, there was strong evidence to suggest that the combination of oestrogen plus 
progestogen via patches was more effective than raloxifene, SSRIs/SNRIs, isoflavones and Chinese 
herbal medicine in relieving VMS. Isoflavones and black cohosh were also found to be better than 
placebo. There was no strong evidence of any other effects among other interventions in the 
network (Table S3). 
High heterogeneity was found between studies, reducing the precision of estimates. This is likely to 
have arisen because of the clinical differences in patients included in the studies – the baseline 
frequency of hot flushes varied considerably between studies. Inconsistency was assessed in the 
closed loop between placebo, sham acupuncture and acupuncture, but no difference was found 
between results obtained through direct and indirect evidence (Table S3). 
 
a. Treatment discontinuation 
A total of 21 RCTs of 10 treatment classes (placebo, oestrogen plus progestogen oral, conjugated 
oestrogens plus bazedoxifene, tibolone, SSRIs/SNRIs, gabapentin, isoflavones, Chinese herbal 
medicine, multibotanicals, valerian root) with a sample size of 4829 women were included in the 
network for discontinuation of treatment (Figure 1, Table S1). Because of high heterogeneity 
between the studies included in the NMA, uncertainty of the results was increased. Inconsistency 
could not be assessed in this network as there were no closed-treatment loops. Only 4 RCTs were at 
high risk of bias. The other 17 were low or moderate risk (Table S2). There was evidence that the 
combination of non-oral oestrogen plus progestogen had significantly lower odds of discontinuation 
than than placebo (OR 0.61 95%CrI (0.37, 0.99). In addition, there was evidence that conjugated 
oestrogens plus bazedoxifene (OR 0.31 95%CrI (0.1, 1.00)) was more effective than placebo in this 
outcome, although there was considerable uncertainty in this result. There was strong evidence that 
SSRIs/SSNIs were worse than placebo (OR 1.66 95%CrI (1.07, 2.61)) on discontinuation of treatment. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
There was evidence that Tibolone and SSRIs/SNRIs were worse than non-oral oestrogen plus 
progestogen and conjugated oestrogens plus bazedoxifene for this outcome (Figure 2B, Table 2, 
Table S4). 
In this analysis, conjugated oestrogens plus bazedoxifene and valerian root were found to have the 
highest probability (37.34% and 37% respectively) of being the best treatments in relation to 
discontinuation of treatment among interventions with duration up to 26 weeks, although note that 
these probabilities are small and below 50%  
 
a. Vaginal bleeding 
The network of vaginal bleeding included five RCTs of 5 treatment classes (placebo, oestrogen plus 
progestogen oral, tibolone, SSRIs/SNRIs, gabapentin) (Figure 1, Table S1) with a sample size of 1367 
women. Neither heterogeneity nor inconsistency could be assessed in the network due to its 
sparseness. A fixed effects model was used and there were no closed-treatment loops. One study 
was at high risk of bias, one was low risk, and the other three were moderate risk (Table S2). The 
sparseness of data within the network meant that there was a high degree of uncertainty in 
estimates, and no conclusions could be drawn regarding effects of treatments on vaginal bleeding 
(adverse event) (Figure 2C, Table S5, Table S6). 
 
Discussion  
This paper summarizes the evidence included in three SRs and analysed in NMAs for the outcomes 
of relief of frequency of VMS, treatment discontinuation and vaginal bleeding among 
pharmacological and non-pharmacological treatments for women with a uterus who have 
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undergone a natural menopause. To our knowledge, this is the first publication using this type of 
complex analysis in the research field of menopause. 
Main findings 
NMA results showed that for women with a uterus, the oestrogen plus progestogen transdermal 
patch was the most effective treatment to relieve the frequency of VMS, with a lower odds of 
discontinuation compared with all the other available treatments (hormonal, non-hormonal and 
non-pharmacological). There was evidence that oestrogen plus progestogen taken orally may be 
more effective to relieve VMS than placebo, but this did not rank as highly as transdermal oestrogen 
plus progestogen in the hierarchy of the best treatment options for this outcome. However, in the 
clinical setting both may be considered as options, depending on the individual’s response to 
treatment. Although isoflavones and black cohosh, were also shown to be more effective than 
placebo in relief of VMS for women with a uterus, there was no evidence that their efficacy differed 
from combined oestrogen plus progestogen. However, these results should be interpreted with 
caution as there was a variety of herbal preparations used in different studies. SSRIs/SNRIs were not 
found to be effective in relieving VMS but were found to have higher odds of discontinuation 
compared to the other treatments, as would be expected due to the serious side effects profile of 
these treatments. However, the NMA demonstrated that women treated with non-oral oestradiol 
plus progestogen or with conjugated oestrogens plus bazedoxifene were less likely to discontinue 
treatment than if they were treated with placebo or tibolone.  
No conclusive points could be made for the outcome of vaginal bleeding for women with a uterus 
given the limited data for this outcome and the lack of inclusion of several interventions in the 
network.  
During the NICE guideline development, results of clinical efficacy from the NMA were incorporated 
into a probabilistic cost-effectiveness analysis that informed the decision-making of the Guideline 
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Committee. The Committeeconcluded that women with a uterus should be offered the treatment of 
oestrogen and progestogen (HRT) for the relief of VMS, following an individualized approach and 
after discussing with them the short-term (up to 5 years) and longer-term benefits and risks. Health 
professionals should not routinely offer selective serotonin reuptake inhibitors (SSRIs), serotonin and 
norepinephrine reuptake inhibitors (SNRIs) or clonidine as first-line treatment for VMS alone and 
should explain to women that although there is some evidence that isoflavones or black cohosh may 
relieve VMS there are health concerns in relation to safety of multiple preparations and interactions 
with other medicines (https://www.nice.org.uk/guidance/ng23/ ) 
Strengths and Limitations 
This is the first NMA designed to include simultaneous comparison of randomized evidence aiming 
to reduce the frequency of VMS for women in menopause. Advanced statistical techniques were 
employed to make best use of available evidence. A novel NMA model which accounts for the nature 
of the VMS data, distributed as overdispersed Poisson, and incorporates class effects and 
transformation of change from baseline scores of outcomes, was developed to make use of as much 
relevant and available data as possible. We were therefore simultaneously able to compare several 
interventions of interest to women and policy makers that had not been compared previously in 
head-to-head trials. 
Overall there were relatively few studies included in the networks compared to the number of 
treatment comparisons. This may have led to the within-class standard deviation parameter not 
being fully informed, which could explain the better fit of the fixed dose effect RE model compared 
to the exchangeable dose effect RE model. A dose-response relationship might have been expected 
in the data, but as the protocol specified that treatments had to be administered within selective 
doses specified in the British National Formulary, the range of doses was often very small. 
Furthermore, body weights and absorption can vary substantially between patients, and this is likely 
to lead to as much (if not more) variation in bioavailability of treatment than the administered dose.  
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Several decisions were made at the protocol stage that impacted the selection of data included in 
the networks and therefore the representativeness of all available evidence in this area. For 
example, we included only English-published studies , which may have limited our evidence on some 
treatments (e.g. Chinese herbal medicines), and publication bias was not easily assessed. 
Furthermore, it was decided to examine the role of different treatments used to reduce the 
frequency rather than the severity of VMS, which resulted in some treatments such as cognitive 
behaviour therapy being excluded from the NMA. The selection of outcomes for inclusion in the 
NMA was based on both their clinical importance and relevance to women in menopause. 
Frequency of VMS, discontinuation and vaginal bleeding were prioritised for inclusion due to their 
high prevalence and availability of evidence. 
Assumptions were also made for the minimum duration of trials for inclusion in the NMA and the 
minimum acceptable criteria for mixed population studies. These assumptions are commonly made 
when a complex meta-analysis is designed and aim to increase the homogeneity and validity of 
included data. However, this resulted in a number of studies being excluded from further analysis. 
Some studies were also excluded because the data reported did not give an indication of variability 
(no information on standard deviation or standard error of results). For the small minority of studies 
that were excluded because they did not connect to the network, their results and whether they 
would influence decision-making were further discussed with the GDG. This information was used as 
supplementary evidence to facilitate the Group’s discussion which recognised the importance of 
these treatments in the management of some women with menopause, especially if they do not 
wish to be treated with pharmacological treatments (such as HRT) and these options were 
highlighted in terms of provision of general advice and information.  
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Interpretation 
This is the first NMA designed to include simultaneous comparison of randomized evidence from 
pharmacological and non-pharmacological treatments aiming to reduce the frequency of VMS for 
women in menopause. After taking into account the assumptions used for this NMA and the 
limitations of this approach, these results provided a comprehensive framework for decision making 
by combing direct and indirect evidence on treatments for the relief of VMS in menopause. Our 
reviewed literature did not identify any other similar type of analysis that could be used for our 
results comparison.   
 
Conclusions 
There is evidence that transdermal oestradiol plus progestogen greatly reduces the frequency of hot 
flushes in women with a uterus. Although there is some evidence of efficacy of oral oestrogen plus 
progestogen treatment, the health economic analysis and the GDG’s expert opinion supported the 
use of both types of oestradiol plus progestogen’s administration in clinical practice.  
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Table 1: Log mean ratios (with their 95% CI) of all interventions in the network and the probability 
of being the best treatment for reducing the frequency of VMS 
Median 
log mean 
ratios 95%CrI 
Probability of being 
the best treatment 
Median (95% CrI) 
treatment rank 
Placebo Reference treatment 0.00% 10 (7-12) 
Sham acupuncture -0.30  (-1.32, 0.64) 1.44% 7 (2-12) 
Oestrogen + progestogen 
non-oral 
-1.46  (-2.37, -0.56) 69.82% 1 (1-5) 
Oestrogen + progestogen oral -0.67  (-1.4, 0.06) 3.73% 4 (1-10) 
Tibolone -0.60  (-1.45, 0.25) 4.02% 5 (1-11) 
Raloxifine 0.50  (-0.49, 1.51) 0.04% 12 (6-12) 
SSRIs/SNRIs -0.17  (-0.61, 0.26) 0.01% 8 (4-11 ) 
Isoflavones -0.48  (-0.82, -0.13) 0.10% 6 (3-9 ) 
Chinese herbal medicine  -0.05  (-0.78, 0.63) 0.09% 9 (4-12 ) 
Black cohosh -0.92  (-1.8, -0.11) 14.23% 3 (1-9 ) 
Multibotanicals  -0.34  (-1.43, 0.73) 2.88% 7 (1-12 ) 
Acupuncture -0.54  (-1.49, 0.31) 3.64% 5 (1-11 ) 
Between-study heterogeneity:  Standard deviation on the log MRs scale (SD) (95% CrI) 0.50 (0.37, 0.70) 
 
Table 2: Log odd ratios (with their 95% CrI) of all interventions in the network and the probability 
of being the best treatment for discontinuation of treatment 
Median log 
odds ratios 95%CrI 
Probability of 
being the best 
treatment 
Median (95% 
CrI) treatment 
rank 
Placebo Reference treatment 0.00% 6 (4-8) 
Oestrogen + progestogen oral -0.50  (-0.99, -0.01) 2.83% 3 (1-6 ) 
Conjugated oestrogens plus 
bazedoxifene  
-1.16  (-2.28, 0.002) 37.34% 2 (1-6 ) 
Tibolone 1.73  (-0.06, 5.15) 0.03% 10 (6-10 ) 
SSRIs/SNRIs 0.50  (0.06, 0.96) 0.00% 8 (6-10 ) 
Gabapentin -0.13  (-0.46, 0.21) 0.08% 5 (3-8 ) 
Isoflavones -0.05  (-0.67, 0.57) 0.29% 6 (2-9 ) 
Chinese herbal medicine  0.46  (-0.86, 1.9) 0.66% 8 (2-10 ) 
Multibotanicals  -0.70  (-2.63, 1.51) 21.77% 3 (1-10 ) 
Valerian root -0.91  (-4.41, 1.69) 37.00% 2 (1-10 ) 
Between-study heterogeneity:  Standard deviation on the log MRs scale (SD) (95% CrI) 0.25 (0.01, 0.70) 
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